NCT00724373View on ClinicalTrials.gov

Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol (Study P05269)(COMPLETED)

CompletedOBSERVATIONAL

Enrollment

442

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions

Hepatitis C, Chronic

Interventions

BIOLOGICAL

Peginterferon alfa-2b (SCH 54031)

Peginterferon alfa-2b plus ribavirin will be administered according to the products' labeling.

DRUG

Ribavirin (SCH 18908)

Peginterferon alfa-2b plus ribavirin will be administered according to the products' labeling.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00724373 - Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol (Study P05269)(COMPLETED) | Biotech Hunter | Biotech Hunter